Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Now is no time to add pressure on businesses: top executives

    Now is no time to add pressure on businesses: top executives
  2. 2

    CJ CheilJedang to spur overseas growth with new Hungary, US plants

    CJ CheilJedang to spur overseas growth with new Hungary, US plants
  3. 3

    Blackpink's solo journeys: Complementary paths, not competition

    Blackpink's solo journeys: Complementary paths, not competition
  4. 4

    Nationwide rail disruptions feared as union plans strike from Dec. 5

    Nationwide rail disruptions feared as union plans strike from Dec. 5
  5. 5

    Seoul to host winter festival from Dec. 13

    Seoul to host winter festival from Dec. 13
  1. 6

    N. Korea, Russia court softer image: From animal diplomacy to tourism

    N. Korea, Russia court softer image: From animal diplomacy to tourism
  2. 7

    Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid

    Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
  3. 8

    [Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts

    [Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
  4. 9

    Main opposition pushes to ease, not postpone, tax on crypto gains

    Main opposition pushes to ease, not postpone, tax on crypto gains
  5. 10

    Actor Song Joong-ki welcomes second child in Rome

    Actor Song Joong-ki welcomes second child in Rome
피터빈트

Celltrion's Truxima hits Britain

By KH디지털2

Published : April 18, 2017 - 16:20

    • Link copied

South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that its biosimilar drug Truxima began selling in Britain following approval from a European regulator.

Starting earlier this month, Britain-based Napp Pharmaceuticals began distributing Celltrion's biosimilar to Roche's Mabthera at 50 hospitals in the country, Celltrion said.

(Yonhap) (Yonhap)

In February, the European Medicines Agency accepted Celltrion's application to sell the antibody biosimilar which is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukemia.

"The first administration of Truxima was completed following the official launch," said a Celltrion official not to be named.

With EMA approval, the biosimilar can also be sold in 28 European Union countries, as well as Norway, Iceland and Lichtenstein, company officials said.

Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. (Yonhap)

More from Headlines